Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein DegradersGlobeNewsWire • 10/23/19
Arvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation SummitGlobeNewsWire • 10/17/19
Arvinas Strengthens Scientific Advisory Board with Leaders in Oncology and Neurological DisordersGlobeNewsWire • 10/02/19
Wedbush Starts Arvinas At Outperform, Says Lead Assets Could Have Successful TrialsBenzinga • 09/25/19
Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC® Protein DegraderGlobeNewsWire • 08/27/19
